However, nowhere have transgenic mice played a larger role than in the development of potential immunotherapies for AD. The initial impetus for immunotherapeutic approaches in AD came from in vitro observations showing that anti-Aβ antibodies could prevent fibril formation and disaggregate preformed fibrils.91 However, without studies in transgenic mice demonstrating potential effectiveness in vivo, it seems unlikely that these approaches would have ever made their way into human trials.
